Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. On May 4, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
Plexium Inc. and AbbVie Inc. entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions.
Novartis forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
Pfizer announced a second collaboration agreement with Arvinas to develop and commercialize the Connecticut-based company’s PROTAC estrogen receptor protein degrader.
Roivant Sciences, the umbrella company for Vivek Ramaswamy’s series of ‘vant companies, acquired Silicon Therapeutics for $450 million in Roivant equity.